Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy | Zendy

Nirosha Mahendraratnam | Zendy; Joel F. Farley | Zendy; Ethan Basch | Zendy; Amber Proctor | Zendy; Stephanie B. Wheeler | Zendy; Stacie B. Dusetzina | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy

Author(s) -

Nirosha Mahendraratnam,

Joel F. Farley,

Ethan Basch,

Amber Proctor,

Stephanie B. Wheeler,

Stacie B. Dusetzina

Publication year - 2019

Publication title -

supportive care in cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.133

H-Index - 112

eISSN - 1433-7339

pISSN - 0941-4355

DOI - 10.1007/s00520-019-04730-3

Subject(s) - medicine , antiemetic , nausea , chemotherapy induced nausea and vomiting , vomiting , guideline , medical prescription , population , aprepitant , intensive care medicine , anesthesia , emergency medicine , pharmacology , environmental health , pathology

Patients initiating highly emetic chemotherapy (HEC) are at a 90% risk of chemotherapy-induced nausea and vomiting (CINV). Despite guideline-concordant antiemetic prescribing preventing CINV in up to 80% of patients, studies suggest that guideline-concordant antiemetic regimen use by patients initiating HEC is sub-optimal. However, these studies have been limited to single-site or single-cancer type with limited generalizability. The objective of this study was to describe antiemetic fill regimens and to assess predictors of underuse in the USA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research